Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone646-975-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.62 million
Profitability
Miscellaneous
Employees79
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its earnings results on Friday, August, 9th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.02. The biotechnology company had revenue of $9.97 million for the quarter, compared to the consensus estimate of $6.40 million. Progenics Pharmaceuticals had a negative return on equity of 65.17% and a negative net margin of 339.86%. View Progenics Pharmaceuticals' Earnings History.
When is Progenics Pharmaceuticals' next earnings date?
What price target have analysts set for PGNX?
4 brokers have issued 1 year price targets for Progenics Pharmaceuticals' stock. Their predictions range from $6.50 to $14.00. On average, they expect Progenics Pharmaceuticals' share price to reach $10.1667 in the next year. This suggests a possible upside of 92.6% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.
What is the consensus analysts' recommendation for Progenics Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.
Has Progenics Pharmaceuticals been receiving favorable news coverage?
Press coverage about PGNX stock has trended negative on Friday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a daily sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Progenics Pharmaceuticals.
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Uniqure (QURE), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Insmed (INSM), Nabriva Therapeutics (NBRV), Tricida (TCDA), Apellis Pharmaceuticals (APLS), Heron Therapeutics (HRTX), Corcept Therapeutics (CORT), Pacira Biosciences (PCRX), Alder Biopharmaceuticals (ALDR), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD) and Aimmune Therapeutics (AIMT).
What other stocks do shareholders of Progenics Pharmaceuticals own?
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Mr. Mark R. Baker, CEO & Director (Age 64)
- Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)
- Mr. Benedict Osorio, Chief Operating Officer (Age 62)
- Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
- Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.90%), Point72 Asset Management L.P. (6.78%), Farallon Capital Management LLC (6.54%), Vanguard Group Inc. (6.45%), Eagle Asset Management Inc. (5.31%) and Rice Hall James & Associates LLC (2.65%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which major investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Ardsley Advisory Partners LP, Wells Fargo & Company MN, Bank of America Corp DE, Invesco Ltd., Pinnacle Associates Ltd., Phocas Financial Corp., Phocas Financial Corp. and Rice Hall James & Associates LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which major investors are buying Progenics Pharmaceuticals stock?
PGNX stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Price T Rowe Associates Inc. MD, Nuveen Asset Management LLC, Vanguard Group Inc., BlackRock Inc., Parametric Portfolio Associates LLC, Virtus ETF Advisers LLC and Point72 Asset Management L.P.. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc and Velan Capital, LP. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $5.28.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $456.30 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.
What is Progenics Pharmaceuticals' official website?
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
